anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Astrocytic necroptosis plays an essential role in the progression and regression of neurological disorders, which contributes to the neuroinflammation and disrupts neuronal regeneration and remyelination of severed axons. Electroacupuncture (EA), an effective therapeutic efficacy against spinal cord injury (SCI), has been proved to reduce neuronal cell apoptosis, inhibit inflammation, and prompt neural stem cell proliferation and differentiations. However, there have been few reports on whether EA regulate astrocytic necroptosis in SCI model. To investigate the effects of EA on astrocytic necroptosis and the mechanisms involved in the inhibition of astrocytic necroptosis after SCI in mice by EA, 8-week-old female C57BL/6 mice were subjected to SCI surgery and randomly divided into EA and SCI groups. Mice receiving sham surgery were included as sham group. "Jiaji" was selected as points for EA treatment, 10 min/day for 14 days. The in vitro data revealed that EA treatment significantly improved the nervous function and pathological changes after SCI. EA also reduced the number of GFAP/P-MLKL, GFAP/MLKL, GFAP/HMGB1, and Iba1/HMGB1 co-positive cells and inhibited the expressions of IL-6, IL-1β, and IL-33. The results indicate a significant reduction in inflammatory reaction and astrocytic necroptosis in mice with SCI by EA. Additionally, the expressions of RIP1, MLKL, and TLR4, which are associated with necroptosis, were found to be downregulated by EA. In this study, we confirmed that EA can inhibit neuroinflammation by reducing astrocytic necroptosis through downregulation of RIP1/MLKL/TLR4 pathway in mice with SCI.
BACKGROUND: Hospitalized patients undergoing surgery or procedures may experience negative symptoms. Music is a nonpharmacological complementary approach and is used as an intervention to reduce anxiety, stress, and pain in these patients. Recently, music has been used conveniently in clinical situations with technology devices, and the mode of providing music is an important factor in technology-based music interventions. However, many reviews have focused only on the effectiveness of music interventions.
OBJECTIVE: We aimed to review randomized controlled trials (RCTs) of technology-based music interventions for reducing anxiety and pain among patients undergoing surgery or procedures. We examined the clinical situation, devices used, delivery methods, and effectiveness of technology-based music interventions in primary articles.
METHODS: The search was performed in the following 5 electronic databases: PubMed, MEDLINE (OvidSP), CINAHL complete, PSYCINFO, and Embase. This systematic review focused on technology-based music interventions. The following articles were included: (1) RCTs, (2) studies using interactive technology (eg, smartphones, mHealth, tablets, applications, and virtual reality), (3) empirical studies reporting pain and anxiety outcomes, and (4) English articles published from 2018 to 2023 (as of January 18, 2023). The risk of bias was assessed using the Cochrane Risk of Bias tool version 2.
RESULTS: Among 292 studies identified, 21 met the inclusion criteria and were included. Of these studies, 9 reported that anxiety scores decreased after music interventions and 7 reported that pain could be decreased before, during, and after procedures. The methodology of the music intervention was important to the results on anxiety and pain in the clinical trials. More than 50% (13/21, 62%) of the studies included in this review allowed participants to select themes themselves. However, it was difficult to distinguish differences in effects depending on the device or software used for the music interventions.
CONCLUSIONS: Technology-based music interventions could help reduce anxiety and pain among patients undergoing surgery or procedures. The findings of this review could help medical teams to choose a practical methodology for music interventions. Future studies should examine the effects of advanced technology-based music interventions using smart devices and software that promote interactions between medical staff and patients.
PROBLEM TO BE SOLVED: To produce an improved cosmetic and a drug preparation for individual use by using a new silicone-ester wax having at least one specific ester part as a substitute for various natural waxes. SOLUTION: This cosmetic contains a silicone-ester wax expressed by formula I (R is H or an organic group; R<1> is >=12C ester-containing group; (a) is 0-3; (b) is 0-3; the average of a+b is a value to give an essentially liner siloxane chain; R<1> is a group derived from a carboxylic acid having an olefinic unsaturated group on the terminal and an alcohol, etc.) and has a melting point of 40-90 deg.C. The R<1> of the wax is especially preferably the group of formula II ((x) and (y) are each an integer of >=4). Preferably, the carboxylic acid is undecylenic acid and the alcohol is stearyl alcohol. The group R<1> is especially preferably derived from trimethylolpropane monoallyl ether and stearic acid. The wax is used as a stick cosmetic such as lipstick, bronze, rouge and eye shadow.
OBJECTIVES: Gastric cancer (GC) is a prevalent malignant tumor widely distributed globally, exhibiting elevated incidence and fatality rates. The gene LAMC2 encodes the laminin subunit gamma-2 chain and is found specifically in the basement membrane of epithelial cells. Its expression is aberrant in multiple types of malignant tumors. This research elucidated a link between LAMC2 and the clinical characteristics of GC and investigated the potential involvement of LAMC2 in GC proliferation and advancement.
MATERIALS AND METHODS: LAMC2 expressions were detected in GC cell lines and normal gastric epithelial cell lines via qRT-PCR. Silencing and overexpression of the LAMC2 were conducted by lentiviral transfection. A xenograft mouse model was also developed for in vivo analysis. Cell functional assays were conducted to elucidate the involvement of LAMC2 in cell growth, migration, and penetration. Further, immunoblotting was conducted to investigate the impact of LAMC2 on the activation of signal pathways after lentiviral transfection.
RESULTS: In the findings, LAMC2 expression was markedly upregulated in GC cell lines as opposed to normal gastric epithelial cells. In vitro analysis showed that sh-LAMC2 substantially inhibited GC cell growth, migration, and invasion, while oe-LAMC2 displayed a contrasting effect. Xenograft tumor models demonstrated that oe-LAMC2 accelerated tumor growth via high expression of Ki-67. Immunoblotting analysis revealed a substantial decrease in various signaling pathway proteins, PI3K, p-Akt, and Vimentin levels upon LAMC2 knockdown, followed by increased E-cadherin expression. Conversely, its overexpression exhibited contrasting effects. Besides, epithelial-mesenchymal transition (EMT) was accelerated by LAMC2.
CONCLUSION: This study provides evidence indicating that LAMC2, by stimulating signaling pathways, facilitated EMT and stimulated the progression of GC cells in laboratory settings and mouse models. Research also explored that the abnormal LAMC2 expression acts as a biomarker for GC.
FIELD: medicine, radionuclide therapy. invention relates to methods of preparing radiotherapeutic preparations labeled with rhenium-188 isotope. SUBSTANCE: lyophilized mixture of reagents has ligand (1-hydroxyethylidene diphosphonic acid), reducing agent (SnCl 2 ·2H 2 O) and an antioxidant (ascorbic acid). To this mixture sterile aqueous solution of perrhenate containing radioactive sodium perrhenate (Na 188 ReO 4 ) obtained in elution of rhenium-188 generator and nonactive rhenium as sodium or potassium perrhenate for increase of rhenium concentration in order to make its concentration in the preparation solution from 10 -4  to 10 -3  mole/l are added. Value of volume activity of the preparation solution is adjusted from 148 to 2960 MBq/ml. Then the preparation is heated at 90-100 C for 15-30 min. The preparation is ready for using after its cooling and solution neutralization to pH 7, not above, at once. Method provides preparing the sterile radiotherapeutic preparation showing high quality indices for optimal short time in clinic conditions. EFFECT: improved method of preparing. 6 cl, 1 ex
FIELD: medicine, dermatology. SUBSTANCE: invention relates to methods of treatment of patients with noninfectious skin diseases. Method involves an effect of skin-pulmonary inhalation on skin using dry sublimation agent containing two plant raw tinctures, Siberian fir coniferous needles, sea-buckthorn juice and an aqueous-spirituous solution that is used for 15-20 min (from one to three seances per a course). The first tincture has rowan melanocarpous, bird cherry and rose fruits and the second one has cedar nuts, mountain-ash fruits, birch buds, marjoram herb, rosewort roots, peppermint leaves, thyme herb, Saint-John's-wort herb, common wormwood herb, pot-marigold flowers, peony roots, licorice roots, Leuzea carthamoides roots taken at definite weight ratio. EFFECT: enhanced effectiveness of treatment, accelerated treatment period. 1 ex, 1 tbl
A skin treatment composition comprising anti-bacterial zeolite and trisalt ethylenediaminehydroxyethyl triacetate. A skin treatment composition comprising anti-bacterial zeolite and alum and/or dried alum. A skin treatment composition comprising anti-bacterial zeolite and polyoxyethylene polyoxypropylene 2-decyltetradecyl ether. <??>The object is to provide a skin treatment composition containing anti-bacterial zeolite that exhibits the effect of preventing discoloration of the skin treatment compositions and/or reducing the degree of discoloration. Another object is to provide a skin treatment composition that is superior in terms of formulation stability and tactile sensation during use. Yet another object is to provide a skin treatment composition having the effect of preventing the skin treatment composition from staining clothing and/or reducing the degree of such staining.
In imaging spectroscopy, gathering oral tissue spectral data from resected samples may not accurately represent tissue signatures due to time-dependent changes, blood loss, protein degeneration, and preservation chemicals. In-vivo spectral imaging is employed to address these limitations, but it poses challenges like device dimensions, tissue accessibility, and motion artifacts, impacting data quality and reliability. Our study publishes a dataset of spectral images focusing on oral diseases, addressing these challenges. We used a state-of-the-art multispectral camera, capturing images at 270*510 pixels resolution in 16 spectral bands (460 nm to 600 nm). The dataset includes 91 participants (15 healthy and 76 diseased), with multiple images per patient, totalling 243 spectral images. The dataset encompasses three oral health conditions: Oral Submucous Fibrosis (OSMF), Leukoplakia, and Oral Squamous Cell Carcinoma (OSCC). Detailed patient history records accompany each case. This publicly available oral health multispectral dataset has the potential to advance spectroscopy diagnosis. Integrating artificial intelligence with a comprehensive spectral signature repository holds promise for accurate disease analysis.
Patients with underlying hepatitis B or C or marked elevations in transaminase prior to treatment may be at increased risk for developing or worsening of transaminase elevations or hepatic decompensation with use of lopinavir and ritonavir. 

  


There have been postmarketing reports of hepatic dysfunction, including some fatalities. These have generally occurred in patients with advanced HIV-1 disease taking multiple concomitant medications in the setting of underlying chronic hepatitis or cirrhosis. A causal relationship with lopinavir and ritonavir therapy has not been established. 

Elevated transaminases with or without elevated bilirubin levels have been reported in HIV-1 mono-infected and uninfected patients as early as 7 days after the initiation of lopinavir and ritonavir in conjunction with other antiretroviral agents. In some cases, the hepatic dysfunction was serious; however, a definitive causal relationship with lopinavir and ritonavir therapy has not been established. 

Appropriate laboratory testing should be conducted prior to initiating therapy with lopinavir and ritonavir and patients should be monitored closely during treatment. Increased AST/ALT monitoring should be considered in the patients with underlying chronic hepatitis or cirrhosis, especially during the first several months of lopinavir and ritonavir treatment [see Use in Specific Populations (8.6)].
The present invention relates to a physiologically active ingredient-nanodiamond complex and a composition comprising the same. Particularly, the present invention relates to a physiologically active ingredient-nanodiamond complex containing a physiologically active ingredient attached to the surface thereof or mixed therein, and a composition comprising the same. The nanodiamond complex according to the present invention can support physiologically active materials for skin. The nanodiamond complex according to the present invention can deliver a physiologically active ingredient into the skin without skin irritation or toxicity. The nanodiamond complex according to the present invention increases effective activity, such as the anti-oxidative activity of a physiologically active material. The nanodiamond complex according to the present invention can support a significant amount of physiologically active material at a molecular level, and thus can provide a pharmacological effect for a long time. In addition, the complex according to the present invention comprises a hydrophilic physiologically active ingredient supported on nanodiamond simultaneously with a hydrophobic physiologically active ingredient, and thus allows permeation of the hydrophilic physiologically active material into the skin stratum corneum. The solubilization method according to the present invention shows the effect of increasing the solubilization efficiency of a physiologically active ingredient by using nanodiamond.
Members of the Waitlist Control arm continued to receive nonconstrained usual care from the Veterans Health Administration. Those initially allocated to the Waitlist Control arm were later provided with the opportunity to cross over and receive the WtoH Intervention after Time 2.
Epicardial adipose tissue (EAT) is an active endocrine organ that is closely associated with occurrence of atrial fibrillation (AF). However, the role of EAT in the development of postoperative AF (POAF) remains unclear. We aimed to investigate the association between EAT profile and POAF occurrence in patients who underwent cardiovascular surgery. We obtained EAT samples from 53 patients to evaluate gene expression, histological changes, mitochondrial oxidative phosphorylation (OXPHOS) capacity in the EAT, and protein secretion in EAT-conditioned medium. EAT volume was measured using computed tomography scan. Eighteen patients (34%) experienced POAF within 7 days after surgery. Although no significant difference was observed in EAT profile between patients with and without POAF, logistic regression analysis identified that the mRNA expression levels of tumor necrosis factor-alpha (TNF-α) were positively correlated and adipocyte size in the EAT was inversely correlated with onset of POAF, respectively. Mitochondrial OXPHOS capacity in the EAT was not associated with POAF occurrence; however, it showed an inverse correlation with adipocyte size and a positive correlation with adiponectin secretion. In conclusion, changes in the secretory profile and adipocyte morphology of the EAT, which represent qualitative aspects of the adipose tissue, were present before the onset of AF.
Chronic kidney disease (CKD) has considerable effects on the quality of life of female patients. Receiving the diagnosis and beginning renal replacement therapy (RRT) has a great personal impact on patients. The purpose of this study was to describe the experience of female patients with CKD at an ambulatory dialysis unit regarding diagnosis, life changes, and initiation of RRT. A qualitative exploratory study was conducted based on a social contructivism framework. Participants were recruited using purposeful sampling. In total, 18 women who received treatment for CKD with RRT were included. The women were attending the Ambulatory Dialysis Unit at a hospital belonging to the public health system of Madrid (Spain). Unstructured and semi-structured in-depth interviews, researchers' field notes, and women's personal letters were used. A systematic text condensation analysis was performed. The criteria used to control trustworthiness were credibility, transferability, dependability, and confirmability. Two themes emerged from the data: (a) A turning point in their lives, and (b) The emotional journey of beginning RRT. The diagnosis of CKD and the beginning of treatment implies changing routines and adapting to a new life with CKD. The first dialysis and puncture of the arteriovenous fistula is a major experience. Support from other CKD patients with more experience is perceived as a necessity and a tool to share their experiences and resolve doubts among peers. The diagnosis and initiation of RRT leads to numerous changes in the lives of women with CKD, which may influence the acceptance of treatment.
This group received pain and pruritus medication as needed, received the usual physical therapy as per the protocol of our burn unit, as well as compression garments, silicone sheets and gels and moisturizing cream twice a day. Additionally, the patients were advice on reducing sun exposure and applying +50SPF sunblock on a daily basis.
This study includes three phases, which each have a separate purpose. At this time, we are only recruiting for Phase 2. The purpose of this particular phase is to measure the effects of niacin after drinking a glass of heavy cream as a source of fat. We hope that studying the way the body responds will help us better understand how niacin works.

In this study, we are interested in niacin's ability to lower triglycerides, or fat in the blood. We are studying two different forms of niacin and comparing them to each other. The two forms differ in how long they take to release niacin into the bloodstream. The first form is called Nialor, and is sometimes called immediate-release niacin because it is absorbed into the bloodstream quickly. The second form is called Niaspan, and is sometimes called extended-release niacin because it is a time-released spansule that takes longer to get into the bloodstream. We are comparing the two forms because we think that the time that it takes to absorb niacin may affect how it works. We also want to understand one of the common effects of niacin: skin flushing. Most people who take niacin experience flushing, which is a hot flash. In this study, we are studying whether the two forms of niacin cause different degrees of flushing. Niaspan is approved by the US Food and Drug Administration (FDA) to treat unfavorable cholesterol levels and prevent heart attacks in those who have already suffered heart attacks. Nialor is available over the counter as a supplement and contains Silymarin (milk thistle) and Policosanol (an extract from sugar cane) in addition to niacin.
AML patients frequently develop cytopenia, which can result in life-threatening bleeding and infections. Despite the administration of prophylactic platelet transfusions, these patients remain at risk of clinically significant hemorrhage. There is a growing need for new, innovative strategies, because the outcome for AML patients, particularly for the older ones, has not substantially changed in the last three decades. Thus, novel compounds to target the tumor cell's resistance to chemotherapeutic agents are essential for the improvement of patients' prognoses. AS101 is a non-toxic, organic, tellurium-based small compound with immunomodulating properties which have previously shown bone marrow sparing effect. In addition in preclinical studies AS101 has shown synergistic effect with several cytotoxic drugs. This study will investigate the safety and efficacy of AS101 formulation in combination with the standard therapy for newly diagnosed elderly AML and AML transformed MDS patients.
A double-blind study was conducted in which 60 healthy subjects were randomized to receive either 6000 Units per kg or 9000 Units per kg VIGIV. After intravenous administration of 6000 Units per kg to 31 healthy subjects, a mean peak plasma concentration of 161 Units per mL was achieved within two hours. The half-life of VIGIV was 30 days (range of 13 to 67 days) and the volume of distribution was 6630 mL. Pharmacokinetic parameters were calculated based on antibody levels determined by an ELISA.

The levels of vaccinia immune globulin remained in circulation for a prolonged period of time, with a mean half-life ranging from approximately 26 to 30 days. Maximum plasma concentrations (Cmax) of VIGIV reached levels ranging from approximately 160 to 232 Units per mL in 1.8 to 2.6 hours. In addition, the drug had a large volume of distribution, as demonstrated by both non-compartmental and compartmental analyses.

Non-compartmental analyses demonstrated that at the two dose levels studied, the drug exhibited dose-proportionality (AUC and Cmax values) (Table 3). The pharmacokinetic parameters estimated by compartmental analysis were similar to those calculated by non-compartmental methods.

The plasma concentration of circulating VIGIV was also compared to a theoretical value obtained from a model of previously licensed Baxter Vaccinia Immune Globulin (VIG) product at Day 5 after IV administration of VIGIV. Since Baxter VIG was administered intramuscularly (IM) and VIGIV is administered IV, the comparison was made at approximately five days to account for equilibration between the extravascular and intravascular compartments following IM injection. 

The binding capacity and neutralizing antibody activity of anti-vaccinia antibody in these subjects five days after intravenous administration of VIGIV (both 6000 Units per kg and 9000 Units per kg dosages) were at least as high as the theoretical values that would be achieved following the intramuscular administration of the comparator VIG (see Table 4). Five days represents the approximate time of peak serum anti-vaccinia antibody concentration following intramuscular administration of other Immune Globulin (Human) products. No historical pharmacokinetic data are available for the theoretical intramuscular comparator VIG.
The present invention discloses a medicinal preparation, a process, a nutritional composition and regenerative and insulin potentiating method for humans and also for mammals for prevention, treatment and glycemic control of diabetes melletus by obtaining optimum glucose level in blood, by administering an extract of Costus pictus to produce above effect in a dose of 500-2000mg/day in humans and 50-200mg/kg/day in rats. This invention also provides a method for treating hyperglycemia in a patient by administering this medicinal preparation, which is an insulin-potentiating agent that decreases blood glucose and/or glycosylated hemoglobin. The invention enables long term management of diabetes by avoiding the problems associated with tight control of blood glucose concentrations, i.e., hypoglycemia tolerance and seizures, while simultaneously avoiding the problems associated with conventional moderate control of blood glucose concentrations, i.e., pathological complications associated with hyperglycemia, such as nephropathy, retinopathy, etc. Blood glucose concentration can be controlled by moderate administration enumerated above of the innovative preparation. In appropriate proportions and with right techniques the preparation can be administered to regenerate beta cells of pancreatic Islets. An innovative extraction of this innovative preparation administered therapeutically deploying an innovative manner and method effectively controls glycogen level in the liver of mammals and humans.